Endo Pharmaceuticals Holdings (ENDP) Tops Q3 EPS by 6c, Reaffirms Guidance
Tweet
Share
E-mailGet Alerts ENDP Hot Sheet
Price: $0.29 --0%
Financial Fact:
Research and development: 28.73M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Research and development: 28.73M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Endo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q3 EPS of $1.25, $0.06 better than the analyst estimate of $1.19. Revenue for the quarter came in at $759 million versus the consensus estimate of $750.26 million.
Company reaffirms 2011 guidance for revenue of $2.72 to $2.80 billion and adjusted diluted EPS of $4.55 to $4.65; now expects reported or GAAP diluted EPS of $1.87 to $1.97.
Company reaffirms 2011 guidance for revenue of $2.72 to $2.80 billion and adjusted diluted EPS of $4.55 to $4.65; now expects reported or GAAP diluted EPS of $1.87 to $1.97.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
- Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
